Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be participating in a live interview with the “Big Biz Show,” an Emmy Award-winning nationally syndicated TV and radio show today, Thursday, August 3rd, 2023 at 3:00 PM ET.
Mark White, CEO of Nexalin Technology, Inc., stated, “I am very excited to discuss recent developments and upcoming milestones regarding our non-invasive, frequency-based, deep-brain stimulation medical devices for treating mental health and addiction disorders. I look forward to speaking with Bob Sullivan and Mike Costa and all The Big Biz Shows listeners.”
The interview will be aired on cable TV and streaming services, including Roku, as well as on radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media in 175 countries.
Podcasts of the show will be available on iHeart Radio, Apple Podcasts, Speaker.com, and TuneIn, as well as to subscribers of biztv.com or ytaclub.com.
About the Big Biz Show
Widely regarded as “Business with a Bite,” the Big Biz Show is an Emmy Award-winning nationally syndicated radio and TV program. The fast-talking, hard-hitting show is hosted by Bob “Sully” Sullivan, who is also a weekly contributor on the FOX Business Network. For more information, go to bigbizshow.com.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp (mA) neurostimulation device was recently approved in China by the National Medical Products Administration (NMPA) for the treatment of insomnia and depression. Additional information about the Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Report on Form 10-K for the year ended December 31, 2022 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
